Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Public ClinicalTrials.gov record NCT01857817. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the clinical benefit of the co-administration of propranolol and etodolac (VT-122 therapy) in patients with clinically progressive prostate cancer.
Study identification
- NCT ID
- NCT01857817
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 35 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2013 (Type not available)
- Primary completion
- Apr 2016 (Actual)
- Completion
- Apr 2016 (Actual)
- Last update posted
- Apr 26, 2018
2013 – 2016
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group | Fayetteville | Arkansas | 72703 | — |
| Redwood Regional Medical Group | Santa Rosa | California | 95403 | — |
| Advanced Urology | Parker | Colorado | 80134 | — |
| Manatee Medical Research Institute, LLC | Bradenton | Florida | 34205 | — |
| Baptist Cancer Institute | Jacksonville | Florida | 32207 | — |
| Midwestern Regional Medical Center | Zion | Illinois | 60099 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Detroit Clinical Research Center, PC | Lansing | Michigan | 48912 | — |
| Adult & Pediatric Urology | Sartell | Minnesota | 56377 | — |
| AccuMed Research Associates | Garden City | New York | 11530 | — |
| Premier Medical Group of the Hudson Valley PC | Poughkeepsie | New York | 12601 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
| Hendrick Cancer Center | Abilene | Texas | 79601 | — |
| Oncology Consultants, P.A. | Houston | Texas | 77030 | — |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | — |
| Medical Oncology Associates, PS | Spokane | Washington | 99208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01857817, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 26, 2018 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01857817 live on ClinicalTrials.gov.